10.50Open10.80Pre Close22 Volume390 Open Interest250.00Strike Price22.30KTurnover34.72%IV2.95%PremiumDec 20, 2024Expiry Date3.07Intrinsic Value100Multiplier19DDays to Expiry7.47Extrinsic Value100Contract SizeAmericanOptions Type0.5875Delta0.0192Gamma25.31Leverage Ratio-0.2218Theta0.0741Rho14.87Eff Leverage0.2278Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet